Objectives: The authors present a case report that proposes the use of cabergoline treatment in silent ACTH adenoma, an unusual member of the heterogeneous group of the so-called clinically non-functioning pituitary adenomas.
Design: Following the clinical and radiological improvement of a recurrent silent ACTH adenoma in a 77-year-old patient treated with cabergoline (0.5 mg every 2 days for 2 years), in vitro studies of the original tumor were performed.
Methods: The original tumor from the patient was studied by in situ hybridization and dopamine D2 receptor autoradiography. It was compared with four macroprolactinomas and two macroadenomas from patients with Cushing's disease.
Results: The D2 receptor mRNA signal of the reported case was intense and of the same order of magnitude as that observed in control prolactinomas. Dopamine D2 receptor autoradiography was twice that of control corticotroph adenomas and was close to that observed in prolactinomas.
Conclusions: This is the first description of an in vivo shrinkage of an ACTH silent adenoma under cabergoline. We demonstrate in vitro, the presence of D2 receptors in the primitive tumor in concentrations similar to those found in control prolactinomas. These results suggest that therapeutic trials with cabergoline might be undertaken in recurring cases of ACTH silent tumors and more generally, non-functioning pituitary adenomas.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1530/eje.0.1440051 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multilineage Pituitary Neuroendocrine Tumors Expressing TPIT and SF1: A Clinicopathological Series of Six Tumors.
Endocr Pathol
December 2024
Derpartment of Pathology, Department of Laboratory Medicine and Pathology, University Health Network, University of Toronto, Toronto, ON, M5G2C4, Canada.
Tumors of adenohypophysial hormone-secreting cells, now classified as pituitary neuroendocrine tumors (PitNETs), have been subclassified based on cell differentiation. Normal adenohypophysial cells have three lineages of differentiation driven by the transcription factors PIT1, TPIT, and SF1 which are responsible for the regulation of hormone gene expression; PIT1 drives expression of GH, PRL, and TSH, TPIT is required for POMC expression that gives rise to ACTH, and SF1 is the transcription factor responsible for FSH and LH expression. The vast majority of PitNETs follow these three lineage differentiation pathways but rare PitNETs show either no lineage differentiation or express biomarkers of more than one lineage.
View Article and Find Full Text PDFTreatment Strategies and Long-Term Outcomes in Silent Corticotroph Adenomas: A Single-Center Retrospective Study of 367 Cases.
Neurosurgery
August 2024
Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Article Synopsis
- Silent corticotroph adenoma (SCA) is a type of aggressive pituitary tumor that can recur even after surgery, and this study aims to analyze long-term outcomes after surgery and suggest optimal post-operative treatments.
- Researchers reviewed data from 367 patients who underwent endoscopic endonasal surgery, categorizing them based on the extent of tumor removal; they measured event-free survival rates across different treatment strategies over an average follow-up period of about 41 months.
- The study found that patients who had a gross total resection (complete tumor removal) had the best outcomes, with lower rates of recurrence compared to those with near total resection or subtotal resection followed by observation or radiation therapy.
Silent Corticotroph Adenomas Demonstrate Predilection for Sphenoid Sinus, Cavernous Sinus, and Clival Invasion Compared with Other Subtypes.
World Neurosurg
November 2024
Department of Neurological Surgery, University of California, Orange, California, USA; Department of Otolaryngology-Head and Neck Surgery, University of California, Orange, California, USA. Electronic address:
Article Synopsis
- Nonfunctional pituitary neuroendocrine tumors (PitNETs), especially silent corticotroph adenomas (SCAs), exhibit distinct growth patterns, with SCAs showing more aggressive invasion into areas like the sphenoid and cavernous sinuses.
- A study analyzed 91 patients who underwent surgery for nonfunctional PitNETs, comparing SCAs with other nonfunctional pituitary adenomas (NFPAs), finding significant differences in growth patterns.
- SCAs are more likely to invade bony structures, while NFPAs tend to grow into the suprasellar space, leading to varying clinical challenges in treatment strategies.
Outcome of non-functioning ACTH pituitary tumors: silent does not mean indolent.
Pituitary
October 2024
Aix Marseille Univ, APHM, INSERM, MMG, Marmara Institute, La Conception University Hospital, Department of Endocrinology, CRMR HYPO, Marseille, France.
Article Synopsis
- Silent corticotroph tumors (siACTH) are rare pituitary tumors that can be more aggressive and have a higher chance of coming back after surgery compared to other types of tumors.
- This study looked at 29 siACTH cases and compared them with two other types of tumors to understand their characteristics and outcomes after surgery.
- The results showed that different grades of siACTH have varying risks of recurrence, suggesting that doctors should keep a close watch on patients with these tumors after they have surgery.
Pathological characteristics of reoperated regrowing clinically nonfunctioning pituitary tumor cases in comparison with initial surgical cases.
Front Endocrinol (Lausanne)
June 2024
Hypothalamic and Pituitary Center, Moriyama Memorial Hospital, Tokyo, Japan.
Objective: Postoperative nonfunctioning pituitary tumor (NFPT) regrowth is a significant concern, but its predictive factors are not well established. This study aimed to elucidate the pathological characteristics of NFPTs indicated for reoperation for tumor regrowth.
Methods: Pathological, radiological, and clinical data were collected from patients who underwent repeat operation for NFPT at Moriyama Memorial Hospital (MMH) between April 2018 and September 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!